Renalytix Share Discussion Threads

[homebrewruss] 19/8/2020 21:39

Good commitment nimbo!
Do you normally take such large percentage portfolio sizes in individual shares?

[nimbo1] 19/8/2020 15:38

just purchased a few : ) GL me

[mr roper] 18/8/2020 10:34

Approval should be coming towards the end of Aug/first week Sept i reckon

[74tom] 18/8/2020 10:17

Cracking post Wan, as soon as I became aware of the qualitative v quantitative antibody testing market it was obvious which one provided long term utility. Once the Kantaro test receives EUA approval I expect we’ll see a lot of publicity. I’m sure Bio-Techne will have this lined up), which will ensure the huge benefits of their test are fully understood.

As a first step I think they should be looking to re-test all those who’ve had results from Roche / Abbott to confirm the exact antibody levels.

The commercials will take care of themselves, all we need is the approval!

[wan] 18/8/2020 07:53

Just to add to the confirmation, I forgot to add the following from the current Mount Sinai FDA Emergency Use Authorisation (EUA) Summary -

COMPONENTS SPECIFIC TO THE TEST
Components specific to the COVID-19 ELISA IgG Antibody Test include the
recombinant RBD protein and the recombinant full-length Spike protein are both
developed at the Mount Sinai Laboratory (MSL).

Mount Sinai Laboratory COVID-19 ELISA IgG Antibody Test EUA Summary

[wan] 18/8/2020 07:46

In an unfortunate way, the following is very important and highlights that Kantaro's groundbreaking antibody test is not only urgently required (10's of millions of tests), but is indeed likely to be the gold standard serology test for COVID-19 -

Abbott, Roche COVID-19 antibody tests may mislead on immunity, study suggests
PUBLISHED
Aug. 17, 2020

Dive Brief:
University of Texas MD Anderson Cancer Center researchers cautioned in a study published on Friday against the "extensive use" of serology tests from Abbott, Roche and other diagnostics companies that only confirm the presence of certain antibodies and may mislead people to falsely believe they have protection against COVID-19 reinfection.

While researchers contend the presence of the so-called S-RBD antibody is the best indicator of any potential protection against reinfection, they warned that widely used serological tests confirm only the presence of antibodies to the N-protein.

Currently, more than 200 commercial and hospital laboratory testing facilities use these N-protein based serology tests for determination of potential COVID-19 immunity, according to researchers. They noted that as of Aug. 5, Abbott has shipped over 13 million serological tests and Roche is expected to produce more than 10 million tests for the U.S. Neither Abbott nor Roche were immediately available for comment regarding the study.

"We caution against the extensive use of N-protein based serology testing for determination of potential COVID-19 immunity, and we believe that accurate and reliable S-RBD serological testing is needed to carefully identify individuals with neutralizing antibodies in order to help advance recovery efforts around the globe," said senior author Raghu Kalluri, chair of cancer biology at MD Anderson, in a written statement.

Full article -

And to confirm, a recent study of the Mount Sinai test, highlighting the use of the S-RBD referred to above, demonstrating that the S protein is highly immunogenic with the receptorbinding domain (RBD) being the target of many neutralizing antibodies and their use -

Published: 12 May 2020
A serological assay to detect SARS-CoV-2 seroconversion in humans

Abstract
Here, we describe a serological enzyme-linked immunosorbent assay for the screening and identification of human SARS-CoV-2 seroconverters. This assay does not require the handling of infectious virus, can be adjusted to detect different antibody types in serum and plasma and is amenable to scaling. Serological assays are of critical importance to help define previous exposure to SARS-CoV-2 in populations, identify highly reactive human donors for convalescent plasma therapy and investigate correlates of protection.

Our data show strong seroconversion with ELISA AUC values in the 1:1,000 range after natural infection with SARS-CoV-2. The results from our assay suggest that antibodies mounted upon infection target the full-length S protein as well as the RBD, which is the major target for neutralizing antibodies for related coronaviruses4

[busterdog2] 17/8/2020 16:49

Thanks, I checked this morning and they weren't but they are now.

[2theduke] 17/8/2020 16:18

@buster - fyi my Verici shares are showing in my Halifax account now.

[nimbo1] 14/8/2020 15:58

News important for momentum. Not been much official since ipo! Things will improve when news flow resumes would be my hunch

[2theduke] 13/8/2020 16:17

This sell down is unnerving, but when I look at the small volume behind it, I calm down - I'll sit steady.
There can not be any big holders moving it down like this, just no one is buying and very few are selling.
It looks like it will keep going down to list price until the news of the FDA approval comes through. GL all.

[nimbo1] 13/8/2020 15:40

tetchy price in the absence of news...

[74tom] 13/8/2020 15:39

Feels very much like a low volume shake down right now - who would have seen this coming with potentially huge news around the corner?! Ignoring the Kantaro EUA, even the commercial launch with Mount Sinai is a real milestone, so I'm watching with no concern right now - will top up if there is a silly spike downwards.

[nimbo1] 12/8/2020 15:27

individual US stock prices can be extremely volatile on news and on selling - just because they have so many pople / money over there. Something we'll be getting used to im sure - including more volatility on news flow - hopefully positive!

[74tom] 12/8/2020 13:50

The pullback is certainly silly, but the market makers know full well they'll get sellers or trigger stop losses, so it's any easy way to get cheap shares. NASDAQ closed at $15.68, which is equivalent to £6, so that should have been the floor really... Overshoot to the downside vs the US, undershoot on the upside - C'est la vie.

[busterdog2] 12/8/2020 13:23

Fear of losing a few quid for some plus yesterday's drop on the Nasdaq. Healthy or not I'd sooner see it going up than down.

[toffeeman] 12/8/2020 13:06

Not sure I understand that pull-back on such light trading.

[wan] 12/8/2020 09:20

A healthy pull back, perhaps created by some being less-than-impressed with the Stifle initiation coverage?

It's always best to be somewhat conservative, especially at this stage ;-)

[74tom] 12/8/2020 08:57

Haha, yes AIM is the rag doll these days! Plenty of newsflow on the way to look forward to :) And thanks as always for the excellent research Wan, plenty of tailwinds to drive RENX commercially.

[nimbo1] 12/8/2020 08:41

Tracking the Nasdaq price in yesterday’s market sell off. Works both ways we can be reassured to know :)

[wan] 11/8/2020 12:36

A relevant post from the EKF thread -

The COVID/healthcare situation has, and is, resulting in rapid changes in the diagnostics and life science sector. And in my view, there is a lot of weight forming behind the dynamics now in play, both associated to and beyond COVID-19, and in which diagnostics will play an increasingly important part.

In this regard, the following article provides for an informative read and a read across to EKF's (and Renalytix) relationship and agreement with Mount Sinai, which provides EKF with advanced access to data and innovative commercial opportunities arising from Mount Sinai Health System owned technologies managed by MSIP in the field of digital diagnostics.

Addressing Covid-19 is a data problem – here’s how the data community is harnessing healthcare data to solve it

Data can allow us to improve our public health response to the pandemic, but only if we enable data scientists with the right tools to harness those datasets.

By FRANK NOTHAFT
Aug 10, 2020

Hospital systems
Digital transformation has been a slow burn for most hospital systems, but Covid-19 has ignited an accelerated effort, especially in the move toward analytics of consolidated health records. Hospitals use multiple different Electronic Health Record (EHR) systems that have complex data storage and analytics architectures. These complex architectures mean that these systems can’t easily interact, making it difficult to collect all the data that will provide a complete picture of a patient, which is necessary for building accurate machine learning models. Ultimately, data scientists working with legacy EHR architectures spend more time freeing data from their EHR, and less time building innovative models that can improve patient outcomes.

Pharmaceutical and diagnostics companies
While hospitals meet immediate healthcare needs and governments focus on controlling the spread, many pharmaceutical and diagnostics companies are focusing their energies on developing diagnostic tests, treatments, and vaccines for Covid-19. These organizations need help analyzing both clinical and real-world observational health data to determine how a drug is being used both in clinical trial settings and compassionate use to treat patients impacted by the virus.

A lot of biopharma and diagnostics companies have been using data about the spread of coronavirus to adjust their clinical trials and manufacturing programs rapidly. With this data, they can make sure that medicines and tests are still getting to patients in need, and they can look at how the novel coronavirus is impacting patients in the disease areas that they are focused on.

Full story -

In short, EKF (and Renalytix) appear well placed for the accelerated revolution taking place in the integration of data and new digital health solutions.

[wan] 11/8/2020 10:49

Thanks Nimbo

[nimbo1] 11/8/2020 10:38

Thanks HB

This from Stifel note confirms commercial testing begins this month.

Initiation Penetration Within Mount Sinai; Other Deals To Follow. This month, the Mount Sinai Hospital System will begin using KidneyIntelX to manage the ~65,000 patients with DKD (Stages 1-3), which should provide a strong initial test volume ramp, particularly given the population health approach being undertaken (wherein implementation will be hospital-wide). Over the next 12 months, additional patient populations within Mount Sinai will likely become eligible for testing, and we expect new accounts to be announced in the form of formal partnerships with other hospital systems and/or payor networks. We also see strong potential for pharma relationships that could yield another key revenue stream going forward.

[homebrewruss] 11/8/2020 10:37

'Stifel (Buy, $22 PT) and JPMorgan (Neutral, $19 PT) initiate on Renalytix $RNLX #RENX this morning
JPM modeling 2025 sales of $254m and 10% operating margin.
Stifel are at $182m for 2025 sales, but have a 16% operating margin by 2023'